Skip to main content
Caplight Logo









BlueSky Immunotherapies GmbH

BlueSky Immunotherapies GmbH

Private
ViennaHealthcare & Life Scienceshttps://www.blueskyvaccines.com/

Last Round

Grant

Nov 1, 2022

Total Funding Raised

$430,000

Momentum

Top 50%

of companies Caplight tracks

Company Overview

BlueSky Immunotherapies GmbH is a biotechnology company that develops next-generation immunotherapies using a proprietary interferon-inducing viral vector technology platform for the treatment of cancer and infectious diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

immunotherapyviral vectorbiotechnologyoncologyhuman papillomavirusHPVcancer vaccinedrug discoveryclinical trialvirotherapysolid tumor treatmentbiotech startupprecision medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

BlueSky Immunotherapies GmbH Comparables

Compare BlueSky Immunotherapies GmbH with similar companies based on industry and business-model similarity.

BlueSky Immunotherapies GmbH comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Nykode Therapeutics
77%
PDS Biotechnology Corp
76%
Hookipa Pharma
75%

BlueSky Immunotherapies GmbH Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantNov 1, 2022

BlueSky Immunotherapies GmbH Investors

Notable investors and investment history

BlueSky Immunotherapies GmbH investors
InvestorRounds
FFG Austrian Research Promotion AgencyGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 16, 2026

    Monthly visitors increased 166% MoM.

  • Apr 2, 2026

    Monthly visitors increased 66% MoM.

BlueSky Immunotherapies GmbH Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

BlueSky Immunotherapies GmbH Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about BlueSky Immunotherapies GmbH's valuation, stock price, and market status.

Firmographic Details

HeadquartersVienna
Employee Range2
Year Founded2013
Last FundingNov 1, 2022

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?